Volumetric tumor growth in advanced NSCLC patients with EGFR mutations during EGFR-TKI therapy: Developing criteria to continue therapy beyond RECIST progression

PURPOSE: Define volumetric tumor growth rate in advanced NSCLC patients with sensitizing EGFR mutations initially treated with EGFR-TKI therapy beyond progression. METHODS: The study included 58 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line gefitinib or erlotinib, w...

Full description

Saved in:
Bibliographic Details
Main Authors: Nishino, Mizuki, Dahlberg, Suzanne E., Cardarella, Stephanie, Jackman, David M., Rabin, Michael S., Ramaiya, Nikhil H., Hatabu, Hiroto, Jänne, Pasi A., Johnson, Bruce E.
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3817609/
https://ncbi.nlm.nih.gov/pubmed/23922022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28290
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items